Rock Springs Capital Management’s Heron Therapeutics HRTX Stock Holding History

Rock Springs Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-30,000	Closed	-$558K	–	143
2019 Q2	$558K	Sell	30,000 -320,000	-91%	-$6.39M	0.02%	134
2019 Q1	$8.55M	Sell	350,000 -175,000	-33%	-$4.58M	0.33%	88
2018 Q4	$13.6M	Hold	525,000	–	–	0.64%	52
2018 Q3	$16.6M	Hold	525,000	–	–	0.6%	59
2018 Q2	$20.4M	Buy	525,000 +49,000	+10%	+$1.56M	0.78%	40
2018 Q1	$13.1M	Buy	476,000 +226,000	+90%	+$5.13M	0.56%	66
2017 Q4	$4.53M	Buy	+250,000	New	+$4.08M	0.21%	109
2015 Q2	–	Sell	-32,500	Closed	-$473K	–	120
2015 Q1	$473K	Sell	32,500 -127,500	-80%	-$1.44M	0.04%	105
2014 Q4	$1.61M	Buy	160,000 +90,000	+129%	+$735K	0.19%	88
2014 Q3	$583K	Buy	+70,000	New	+$652K	0.09%	81

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Rock Springs Capital Management's HRTX Position: Q3 2019 in Review

Rock Springs Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2019, closing a stake of 30,000 shares — an estimated $558K sold.

Rock Springs Capital Management first reported a position in HRTX in Q3 2014 and held it in 10 quarters. The position peaked at $20.4M in Q2 2018. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

Rock Springs Capital Management reported no remaining Heron Therapeutics position as of Q3 2019 after selling out during the quarter.
Rock Springs Capital Management sold 30,000 Heron Therapeutics shares in Q3 2019, an estimated $558K.
Rock Springs Capital Management first reported a position in Heron Therapeutics in Q3 2014 and held it in 10 quarters.
Rock Springs Capital Management's Heron Therapeutics position peaked at $20.4M in Q2 2018.
180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Rock Springs Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.